Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
1.
Robert  CSoria  JCSpatz  A  et al.  Cutaneous side-effects of kinase inhibitors and blocking antibodies.  Lancet Oncol 2005;6 (7) 491- 500PubMedGoogle ScholarCrossref
2.
Strumberg  D Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.  Drugs Today (Barc) 2005;41 (12) 773- 784PubMedGoogle ScholarCrossref
3.
Zakarija  ASoff  G Update on angiogenesis inhibitors.  Curr Opin Oncol 2005;17 (6) 578- 583PubMedGoogle ScholarCrossref
4.
Wilhelm  SMCarter  CTang  L  et al.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.  Cancer Res 2004;64 (19) 7099- 7109PubMedGoogle ScholarCrossref
5.
Awada  AHendlisz  AGil  T  et al.  Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.  Br J Cancer 2005;92 (10) 1855- 1861PubMedGoogle ScholarCrossref
6.
Clark  JWEder  JPRyan  DLathia  CLenz  HJ Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.  Clin Cancer Res 2005;11 (15) 5472- 5480PubMedGoogle ScholarCrossref
7.
Strumberg  DRichly  HHilger  RA  et al.  Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.  J Clin Oncol 2005;23 (5) 965- 972PubMedGoogle ScholarCrossref
8.
Escudier  BEisen  TStadler  WM  et al.  Sorafenib in advanced clear-cell renal-cell carcinoma [published correction appears in N Engl J Med. 2007;357(2):203].  N Engl J Med 2007;356 (2) 125- 134PubMedGoogle ScholarCrossref
9.
Escudier  BSCEisen  T Randomized phase III trial of the Raf kinase and VEGF inhibitor sorafenib (BAY 439006) in patients with advanced renal cell carcinoma [ASCO meeting abstract 4510].  J Clin Oncol 2005;233805Google Scholar
10.
Ratain  MJEisen  TStadler  WM  et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.  J Clin Oncol 2006;24 (16) 2505- 2512PubMedGoogle ScholarCrossref
11.
 ASCO 2007: plenary top 5.  Oncology (Williston Park) 2007;21 (7) 896PubMedGoogle Scholar
12.
Moore  MHirte  HWSiu  L  et al.  Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.  Ann Oncol 2005;16 (10) 1688- 1694PubMedGoogle ScholarCrossref
13.
Trotti  AByhardt  RStetz  J  et al.  Common toxicity criteria: version 2.0: an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.  Int J Radiat Oncol Biol Phys 2000;47 (1) 13- 47PubMedGoogle ScholarCrossref
14.
Baack  BRBurgdorf  WH Chemotherapy-induced acral erythema.  J Am Acad Dermatol 1991;24 (3) 457- 461PubMedGoogle ScholarCrossref
15.
Susser  WSWhitaker-Worth  DLGrant-Kels  JM Mucocutaneous reactions to chemotherapy.  J Am Acad Dermatol 1999;40 (3) 367- 398PubMedGoogle ScholarCrossref
16.
Strumberg  DAwada  AHirte  H  et al.  Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome?  Eur J Cancer 2006;42 (4) 548- 556PubMedGoogle ScholarCrossref
17.
Robert  CFaivre  SRaymond  EArmand  JPEscudier  B Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?  Ann Intern Med 2005;143 (4) 313- 314PubMedGoogle ScholarCrossref
18.
Peréz-Soler  RSaltz  L Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?  J Clin Oncol 2005;23 (22) 5235- 5246PubMedGoogle ScholarCrossref
19.
Kong  HHCowen  EWAzad  NSDahut  WGutierrez  MTurner  ML Keratoacanthomas associated with sorafenib therapy.  J Am Acad Dermatol 2007;56 (1) 171- 172PubMedGoogle ScholarCrossref
20.
Lacouture  MEDesai  ASoltani  K  et al.  Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.  Clin Exp Dermatol 2006;31 (6) 783- 785PubMedGoogle ScholarCrossref
21.
Motzer  RJBacik  JSchwartz  LH  et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.  J Clin Oncol 2004;22 (3) 454- 463PubMedGoogle ScholarCrossref
Study
July 21, 2008

Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor

Author Affiliations

Author Affiliations: Dermatology Unit (Drs Autier and Robert) and Immunotherapy Unit (Dr Escudier), Department of Medicine, and Pathology Department (Dr Spatz), Gustave Roussy Institute, Villejuif, France; and Pathology Department, Henri-Mondor Hospital, Creteil, France (Dr Wechsler).

Arch Dermatol. 2008;144(7):886-892. doi:10.1001/archderm.144.7.886
Abstract

Objectives  To provide an accurate description and to evaluate the incidence and severity of cutaneous reactions induced by sorafenib tosylate, a new oral multikinase inhibitor.

Design  Double-blind, prospective dermatologic substudy performed on all consecutive patients included in our center in a large phase 3 trial.

Setting  Institutional practice at the Gustave Roussy Institute.

Patients  Eighty-five patients with renal cell cancer treated between November 1, 2003, and February 28, 2005.

Interventions  Patients were randomized to receive either sorafenib (n = 43) or placebo (n = 42). Dermatologic examination was performed before treatment, every 3 weeks during the first 4 cycles, and every 4 weeks thereafter.

Main Outcome Measures  Incidence and severity of cutaneous reactions to sorafenib.

Results  Thirty-nine patients (91%) experienced at least 1 cutaneous reaction in the sorafenib group vs 3 (7%) in the placebo group. A hand-foot skin reaction that appeared to be clinically distinct from the well-known chemotherapy-induced hand-foot syndrome was observed in 26 patients receiving sorafenib (60%). Reversible grade 3 hand-foot skin reaction was documented in 2 patients receiving sorafenib and led to a dose reduction. Other cutaneous reactions were facial erythema, scalp dysesthesia, alopecia, and subungual splinter hemorrhages.

Conclusions  Sorafenib induces frequent cutaneous adverse events, some of which may lead to a dose reduction. Close collaboration between oncologists and dermatologists is needed to improve both the characterization and the management of these side effects. Appropriate patient education before the initiation of therapy and the introduction of early symptomatic measures may improve management.

×